Synthesis and characterization of novel pyrimidine-4,5-diamine as anticancer agent

Abstract

Unlike latent cells, cancer cells supply deoxyribonucleoside triphosphates to cells continuously and thereby, prop up the uncontrolled cancer growth. Pyrimidine has been concerned in the separation of leukemic cells, known as adenine bioisosteres, as well as its biological activities, especially its anticancer properties. In this context, a novel series of N5-(3-substituted benzylidene)-N4-phenyl pyrimidine-4,5-diamine [5A-5F] / N5-(2-substituted benzylidene)-N2,N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine [5a-5f] were synthesized by using the starting ingredient formimidamide/4(dimethylamino) benzimidamide and sodium ethoxide. The synthesized compounds were characterized by IR,1H NMR, and Mass spectral analyses and screened for their biological studies. In the present study, pyrimidine derivatives and their insilico modeling were done by using c-Src kinase and p38 MAP kinase complex followed by the evaluation of their anticancer activity. The screening of synthesized scaffolds possessed significant activity against HeLa cell lines and showed similar activity compared to standard Cisplatin. Among all the synthesized compounds, N5-(4-hydroxybenzylidene)-N4-phenyl pyrimidine-4,5-diamine 5A, N5benzylidene-N4-phenylpyrimidine-4,5-diamine 5C, N5-benzylidene-N2, N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine 5c, and N5-(4-methoxy benzylidene)-N4-phenyl pyrimidine-4,5-diamine 5E showed the highest significant anticancer activity.